Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238
Journal of Clinical Oncology · 2024
DOI: 10.1200/jco.23.01448 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, 2024. Verfasst von Jeffrey Weber und 25 weiteren Autor:innen. Beteiligte Einrichtung: Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY. Hauptthemen laut MEDLINE: Melanoma, Immune Checkpoint Inhibitors, Nivolumab, Ipilimumab. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE In phase III CheckMate 238, adjuvant nivolumab significantly improved recurrence-free survival compared with ipilimumab in patients with resected stage IIIB-C/IV melanoma without a significant difference in overall survival (OS). Here, we investigate progression-free survival (PFS) and OS after postrecurrence systemic therapy. PATIENTS AND METHODS Patients 15 years or older with resected stage IIIB-C/IV melanoma were stratified by stage and tumor PD-L1 status and randomly assigned to receive nivolumab 3 mg/kg every 2 weeks, or ipilimumab 10 mg/kg every 3 weeks for four doses and then every 12 weeks for 1 year or until disease recurrence, unacceptable toxicity, or withdrawal of consent. Patients with recurrence in each group were assessed for PFS and OS from subsequent systemic therapy (SST) initiation per recurrence timing (≤12 months [early] v >12 months [late] from initial therapy). RESULTS Recurrences occurred in 198 (44%) of 453 nivolumab-treated patients (122 early, 76 late) and 232 (51%) of 453 ipilimumab-treated patients (160 early, 72 late). Median PFS on next-line systemic therapy for nivolumab-treated patients recurring early versus late was 4.7 versus 12.4 months (24-month rates, 16% v 31%); median OS was 19.8 versus 42.8 months (24-month rates: 37% v 73%). In response to subsequent therapy, patients on nivolumab with late versus early recurrence were more likely to benefit from anti–PD-1 monotherapy. Nivolumab-treated patients with either an early or late recurrence benefitted from an ipilimumab-based therapy or targeted therapy, each with similar OS. CONCLUSION Postrecurrence survival was longer for patients who recurred >12 months. Patients on nivolumab who recurred early benefitted from SST but had better survival with ipilimumab-based regimens or targeted therapy compared with anti–PD-1 monotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY.
- Unit of Melanoma Medical Oncology, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
- Papa Giovanni XIII Hospital, Bergamo, Italy.
- Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece.
- Department of Medical Oncology, Hospital Clínic de Barcelona-IDIBAPS, Barcelona, Spain.
- Department of Dermatology, Hospices Civils de Lyon, Pierre Bénite, France.
ORCID-Profile: Jeffrey Weber, Mario Mandalá, Helen Gogas, Michael Schenker, Jean-Jacques Grob, Vanna Chiarion-Sileni, Iván Márquez-Rodas, Marcus O Butler, Luis de la Cruz-Merino, Petr Arenberger, Leslie A Fecher, Michael Millward, Nikhil I Khushalani, Georgina V Long, Maurice Lobo, Paolo A Ascierto, James Larkin
Zitieren
APA
Weber, J., Del Vecchio, M., Mandalá, M., Gogas, H., Arance, A. M., Dalle, S., Cowey, C. L., Schenker, M., Grob, J. J., Chiarion-Sileni, V., Márquez-Rodas, I., Butler, M. O., Di Giacomo, A. M., de la Cruz-Merino, L., Arenberger, P., Atkinson, V., Hill, A., Fecher, L. A., Millward, M., …, & Larkin, J. (2024). Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238. Journal of Clinical Oncology. https://doi.org/10.1200/jco.23.01448
Vancouver
Weber J, Del Vecchio M, Mandalá M, Gogas H, Arance AM, Dalle S, et al. Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238. Journal of Clinical Oncology. 2024. doi:10.1200/jco.23.01448
BibTeX
@article{Weber2024,
author = {Weber, Jeffrey and Del Vecchio, Michele and Mandalá, Mario and Gogas, Helen and Arance, Ana M and Dalle, Stephane and Cowey, C Lance and Schenker, Michael and Grob, Jean-Jacques and Chiarion-Sileni, Vanna and Márquez-Rodas, Iván and Butler, Marcus O and Di Giacomo, Anna Maria and de la Cruz-Merino, Luis and Arenberger, Petr and Atkinson, Victoria and Hill, Andrew and Fecher, Leslie A and Millward, Michael and Khushalani, Nikhil I and Queirolo, Paola and Long, Georgina V and Lobo, Maurice and Askelson, Margarita and Ascierto, Paolo A and Larkin, James},
title = {Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238},
journal = {Journal of Clinical Oncology},
year = {2024},
doi = {10.1200/jco.23.01448}
}
EUVIMED